| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12264-017-0202-6 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1007/s12264-017-0202-6 |
| P8608 | Fatcat ID | release_gixfyl6fqzfuteguqyd7xnfvvq |
| P932 | PMC publication ID | 5856723 |
| P698 | PubMed publication ID | 29282614 |
| P50 | author | Chuantao Zuo | Q88048427 |
| Zhen-Yang Liu | Q89743936 | ||
| P2093 | author name string | Jian Wang | |
| James B Koprich | |||
| Feng-Tao Liu | |||
| P2860 | cites work | Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study | Q44147105 |
| Endogenous dopamine release after pharmacological challenges in Parkinson's disease. | Q44429895 | ||
| Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study | Q44499883 | ||
| Striatal dopamine release induced by repetitive transcranial magnetic stimulation of the human motor cortex | Q44560637 | ||
| A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease | Q44571920 | ||
| Role of dopaminergic treatment in dopamine receptor down-regulation in advanced Parkinson disease: a positron emission tomographic study | Q45144710 | ||
| Microglial activation and dopamine terminal loss in early Parkinson's disease | Q45237159 | ||
| An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28 | Q24599479 | ||
| Toward discovery science of human brain function | Q24619932 | ||
| Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects | Q24631118 | ||
| Translocator protein 18 kDa (TSPO): molecular sensor of brain injury and repair | Q24644752 | ||
| MIBG myocardial scintigraphy in pre-motor Parkinson's disease: a review | Q26830280 | ||
| Consistent abnormalities in metabolic network activity in idiopathic rapid eye movement sleep behaviour disorder | Q27303962 | ||
| Staging of brain pathology related to sporadic Parkinson's disease | Q28131702 | ||
| Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease | Q28192834 | ||
| Tau imaging: early progress and future directions | Q28253740 | ||
| Dermatologist-level classification of skin cancer with deep neural networks | Q28528865 | ||
| Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder | Q30493368 | ||
| Increase in dopamine turnover occurs early in Parkinson's disease: evidence from a new modeling approach to PET 18 F-fluorodopa data | Q30671310 | ||
| The neural basis of functional brain imaging signals | Q30748114 | ||
| Neuroimaging in Parkinson disease: from research setting to clinical practice | Q30868628 | ||
| Biomarkers for dementia and mild cognitive impairment in Parkinson's disease | Q31097119 | ||
| Assessment of the progression of Parkinson's disease: a metabolic network approach | Q31130371 | ||
| Looking into the functional architecture of the brain with diffusion MRI. | Q33187218 | ||
| Visualizing vesicular dopamine dynamics in Parkinson's disease. | Q46038187 | ||
| Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics | Q46151649 | ||
| Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity | Q46378697 | ||
| Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C]NNC 112 and [18F]FDOPA. | Q46574790 | ||
| PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation | Q46635617 | ||
| Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways | Q46848027 | ||
| Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease | Q46900351 | ||
| Validation of parkinsonian disease-related metabolic brain patterns | Q47907731 | ||
| DAT imaging and clinical biomarkers in relatives at genetic risk for LRRK2 R1441G Parkinson's disease. | Q47907932 | ||
| White matter fiber tractography: why we need to move beyond DTI. | Q48104328 | ||
| Metabolic brain network in the Chinese patients with Parkinson's disease based on 18F-FDG PET imaging. | Q48110466 | ||
| Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study | Q48115841 | ||
| Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains | Q48187073 | ||
| Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series | Q48195826 | ||
| Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease | Q48206843 | ||
| Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease | Q48279042 | ||
| Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. | Q48290740 | ||
| Parkinson's disease patients show reduced cortical-subcortical sensorimotor connectivity. | Q48299639 | ||
| Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. | Q48552867 | ||
| Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation. | Q48557730 | ||
| Advanced diffusion MRI fiber tracking in neurosurgical and neurodegenerative disorders and neuroanatomical studies: A review. | Q48601965 | ||
| Frequency-dependent neural activity in Parkinson's disease. | Q48647768 | ||
| Decreased striatal dopaminergic innervation in REM sleep behavior disorder. | Q48709549 | ||
| Cortical hypoperfusion in Parkinson's disease assessed using arterial spin labeled perfusion MRI. | Q48813269 | ||
| Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. | Q48822647 | ||
| Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations. | Q48829872 | ||
| Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease. | Q48955021 | ||
| Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. | Q49109464 | ||
| Corpus callosum and cingulum tractography in Parkinson's disease. | Q50692786 | ||
| Progression of monoaminergic dysfunction in Parkinson's disease: a longitudinal 18F-dopa PET study. | Q51160375 | ||
| Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. | Q51421607 | ||
| Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. | Q51431445 | ||
| [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism. | Q53145769 | ||
| In vivo DA D(1) receptor selectivity of NNC 112 and SCH 23390. | Q53483950 | ||
| Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts | Q57089099 | ||
| In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease | Q64786334 | ||
| Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy | Q64902706 | ||
| The vesicular monoamine transporter is not regulated by dopaminergic drug treatments | Q71377126 | ||
| Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients | Q71778440 | ||
| The metabolic topography of parkinsonism | Q72136177 | ||
| Posterior hypoperfusion in Parkinson's disease with and without dementia measured with arterial spin labeling MRI | Q83746062 | ||
| Neuroimaging for Lewy body disease: is the in vivo molecular imaging of α-synuclein neuropathology required and feasible? | Q33649354 | ||
| Clinical and [18F] dopa PET findings in early Parkinson's disease | Q33734819 | ||
| Abnormalities in metabolic network activity precede the onset of motor symptoms in Parkinson's disease | Q33835425 | ||
| Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review | Q33867444 | ||
| Network modulation following sham surgery in Parkinson's disease. | Q33944241 | ||
| Applications of arterial spin labeled MRI in the brain | Q34128055 | ||
| Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study | Q34160601 | ||
| Parkinson's disease spatial covariance pattern: noninvasive quantification with perfusion MRI | Q34170874 | ||
| Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation | Q34171364 | ||
| A disease-specific metabolic brain network associated with corticobasal degeneration | Q34399253 | ||
| MDS clinical diagnostic criteria for Parkinson's disease | Q34498274 | ||
| Levodopa and the progression of Parkinson's disease | Q34553278 | ||
| Imaging prodromal Parkinson disease: the Parkinson Associated Risk Syndrome Study | Q34553777 | ||
| Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis | Q34601225 | ||
| Brain serotonin transporter binding in non-depressed patients with Parkinson's disease | Q34619565 | ||
| Arterial spin labelling reveals an abnormal cerebral perfusion pattern in Parkinson's disease | Q35018093 | ||
| Resting-state functional MR imaging: a new window to the brain | Q35193247 | ||
| Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation | Q35490116 | ||
| Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's disease | Q35564787 | ||
| Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review | Q35603195 | ||
| Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease | Q35679727 | ||
| Changes in network activity with the progression of Parkinson's disease | Q35679748 | ||
| Abnormal metabolic network activity in Parkinson's disease: test-retest reproducibility. | Q35683286 | ||
| Metabolic brain networks associated with cognitive function in Parkinson's disease | Q35684482 | ||
| Network modulation in the treatment of Parkinson's disease | Q35694166 | ||
| Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease | Q35711351 | ||
| Imaging Striatal Microglial Activation in Patients with Parkinson's Disease. | Q35779298 | ||
| Abnormal metabolic brain networks in a nonhuman primate model of parkinsonism | Q35866836 | ||
| GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding | Q35983900 | ||
| Metabolic brain networks in translational neurology: concepts and applications | Q36041821 | ||
| Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease | Q36053272 | ||
| Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. | Q36071428 | ||
| Parkinson's disease: in vivo assessment of disease progression using positron emission tomography | Q36080010 | ||
| CSF Biomarkers and Its Associations with 18F-AV133 Cerebral VMAT2 Binding in Parkinson's Disease-A Preliminary Report | Q36169215 | ||
| Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis | Q36198606 | ||
| Assessing cerebral glucose metabolism in patients with idiopathic rapid eye movement sleep behavior disorder. | Q36350514 | ||
| Region-Specific Iron Measured by MRI as a Biomarker for Parkinson's Disease | Q36374541 | ||
| Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia | Q36475260 | ||
| Striatal and Cortical β-Amyloidopathy and Cognition in Parkinson's Disease | Q36494215 | ||
| Parkinson's disease: pathophysiology | Q36495393 | ||
| D3 dopamine receptor-preferring [11C]PHNO PET imaging in Parkinson patients with dyskinesia | Q36521275 | ||
| The influence of the amplitude of low-frequency fluctuations on resting-state functional connectivity | Q36732955 | ||
| Tau imaging in neurodegenerative diseases | Q36834567 | ||
| Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs | Q36984958 | ||
| Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease | Q37056546 | ||
| Multiclass classification of FDG PET scans for the distinction between Parkinson's disease and atypical parkinsonian syndromes | Q37185684 | ||
| Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons | Q37406074 | ||
| History of falls in Parkinson disease is associated with reduced cholinergic activity | Q37459699 | ||
| A timeline for Parkinson's disease | Q37619101 | ||
| Abnormal metabolic network activity in REM sleep behavior disorder | Q37658353 | ||
| 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis | Q37982898 | ||
| Dyskinesias in Parkinson's disease: views from positron emission tomography studies | Q38182651 | ||
| Molecular imaging insights into neurodegeneration: focus on α-synuclein radiotracers | Q38236857 | ||
| Molecular imaging of dopamine transporters | Q38708791 | ||
| Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels | Q39113010 | ||
| Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography. | Q39205398 | ||
| Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease | Q39429074 | ||
| Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient | Q39434658 | ||
| In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. | Q39758264 | ||
| Automated Differential Diagnosis of Early Parkinsonism Using Metabolic Brain Networks: A Validation Study. | Q40451216 | ||
| [3H]methoxytetrabenazine: a high specific activity ligand for estimating monoaminergic neuronal integrity | Q40970321 | ||
| Extrastriatal dopaminergic abnormalities of DA homeostasis in Parkinson's patients with medication-induced pathological gambling: a [11C] FLB-457 and PET study. | Q42077769 | ||
| Neurite orientation dispersion and density imaging in the substantia nigra in idiopathic Parkinson disease. | Q42484375 | ||
| In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease | Q42484469 | ||
| Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures | Q42794711 | ||
| Dopamine turnover increases in asymptomatic LRRK2 mutations carriers | Q42861721 | ||
| Typical cerebral metabolic patterns in neurodegenerative brain diseases | Q42952840 | ||
| Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study | Q42994792 | ||
| Serotonin 2A receptors and visual hallucinations in Parkinson disease | Q43102377 | ||
| Longitudinal progression of sporadic Parkinson's disease: a multi-tracer positron emission tomography study | Q43290056 | ||
| Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson's disease | Q43296929 | ||
| Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. | Q43526336 | ||
| Metabolic correlates of levodopa response in Parkinson's disease | Q43820136 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 330-340 | |
| P577 | publication date | 2017-12-27 | |
| P1433 | published in | Neuroscience Bulletin | Q15764540 |
| P1476 | title | Update on Molecular Imaging in Parkinson's Disease | |
| P478 | volume | 34 |
Search more.